Maressa A. Bruhn - Concepedia

Author

Maressa A. Bruhn

The University of Adelaide

Also Known As

M A Bruhn, M. Bruhn, M.A. Bruhn, Maressa A. Bruhn, Maressa Bruhn

Publications

445

Citations

H-Index

Concepts

All Affiliations

The University of Adelaide Queen Elizabeth Hospital Basil Hetzel Institute The University of Sydney National Health and Medical Research Council

About

Maressa A. Bruhn is an author at The University of Adelaide specializing in oncology, colorectal cancer, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	49
2	Pathology	2	2	49
3	Cell Biology	1	1	18
4	Immunology	1	1	31
5	Cancer Therapeutics	1	1	31

Maressa A. Bruhn

Publications

284

Citations

H-Index

Page 1

	Year	Citations
Nasal Mucosa Expression of Lactoferrin in Patients With Chronic Rhinosinusitis Alkis J. Psaltis, Maressa A. Bruhn, Eng H. Ooi, The Laryngoscope	2007	78
Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro Hilary Dorward, Alice W. Du, Maressa A. Bruhn, Journal of Experimental & Clinical Cancer Research	2016	74
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer Timothy Price, Maressa A. Bruhn, Chee Khoon Lee, British Journal of Cancer	2015	39
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer Maressa A. Bruhn, Amanda Townsend, Chee Khoon Lee, International Journal of Cancer Prognostic BiomarkersMedicineImmunologyMultiplex ProteinColorectal Cancer	2013	31
Response of Peripheral Blood Lymphocytes to Fungal Extracts and Staphylococcal Superantigen B in Chronic Rhinosinusitis Richard Douglas, Maressa A. Bruhn, Lorwai Tan, The Laryngoscope	2007	28
High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab Shalini Sree Kumar, Yoko Tomita, Joe Wrin, Clinical & Translational Oncology MedicinePoorer OutcomeColorectal CancerPathologyAnti-egfr Treatment	2016	18
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer Fiona Chionh, Val Gebski, Sheren Al-Obaidi, Scientific Reports	2022	16

Page 1